Besnoitia besnoiti is an emerging apicomplexan parasite that causes bovine besnoitiosis. Found originally in Africa, and now in many European countries. It causes, among many other things, decreased milk production, sterility in bulls, and an increased mortality rate, which all have severe economic affects. Currently, there is no cure, no publicly available genome sequence, and only a very unreliable vaccine. Our goal is to develop a new drug for the treatment of bovine besnoitiosis. To do this, we will find compounds that inhibit the enzymes that are crucial for the survival of B. besnoiti. Calcium dependant protein kinases (CDPKs) have shown to be promising targets in other closely related enzymes. They are essential for the survival of the parasite and can be targeted by bumped kinase inhibitors (BKIs) which bind to the ATP binding site of these enzymes. We have identified, cloned, expressed, and assayed recombinant BbCDPK1 for the inhibition of its enzyme activity with 63 BKI analogs using previously described luciferase assay. BbCDPK1 was inhibited by low concentrations of BKIs. Experiments so far have had around a 90% inhibition rate, and four compounds in particular have been very effective with only small amounts of compound. Further experiments are planned in vivo, as the BKIs have shown no toxicity in cattle. Our studies thus far indicate that this strategy could lead to non-toxic, selective CDPK1 inhibitors with good PK properties, and are thus excellent leads for further besnoitiosis drug development programs.